ES2192394T3 - Profarmacos de inhibidores de la bomba de protones. - Google Patents
Profarmacos de inhibidores de la bomba de protones.Info
- Publication number
- ES2192394T3 ES2192394T3 ES99942057T ES99942057T ES2192394T3 ES 2192394 T3 ES2192394 T3 ES 2192394T3 ES 99942057 T ES99942057 T ES 99942057T ES 99942057 T ES99942057 T ES 99942057T ES 2192394 T3 ES2192394 T3 ES 2192394T3
- Authority
- ES
- Spain
- Prior art keywords
- carbons
- alkyl
- alkoxy
- substituted
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940126409 proton pump inhibitor Drugs 0.000 title 1
- 239000000612 proton pump inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 30
- 125000003545 alkoxy group Chemical group 0.000 abstract 27
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 14
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 229910052731 fluorine Inorganic materials 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 6
- 239000011737 fluorine Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 abstract 5
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- -1 N-substituted carbamoyl Chemical group 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001326 naphthylalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000002071 phenylalkoxy group Chemical group 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Reciprocating Pumps (AREA)
- Fertilizing (AREA)
Abstract
Un compuesto de la fórmula Het1 - X - S(O)- Het2 en donde Het1 se selecciona a partir del grupo que consta de las estructuras mostradas por las fórmulas a continuación **(Fórmula)** X se selecciona a partir del grupo que consta de las estructuras mostradas por las fórmulas a continuación **(Fórmula)** y Het2 se selecciona a partir del grupo consistente en las estructuras mostradas por las fórmulas a continuación **(Fórmula)** en donde N en el resto bencimidazol representa que uno de los carbonos del anillo se puede intercambiar por un átomo de N no sustituido; **(Fórmula)** R1, R2 y R3 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con flúor, alcoxi de 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con flúor, alquiltio de 1 a 10 carbonos, alquiltio de 1 a 10 carbonos sustituido con flúor, alcoxialcoxi de 2 a 10 carbonos, amino, alquilamino y dialquilamino teniendo cada uno de los grupos alquilo en dichos grupos alquilamino y dialquilamino 1 a 10 carbonos, halógeno, fenilo, fenilo sustituido con alquilo, fenilo sustituido con alcoxi, fenilalcoxi, teniendo cada uno de los grupos alquilo en dicho fenilo sustituido con alquilo, fenilo sustituido con alcoxi y fenilalcoxi, 1 a 10 carbonos, piperidino, morfolino o dos de los grupos R1, R2y R3 forman conjuntamente un anillo de 5 o 6 miembros que tienen 0 o 1 heteroátomo seleccionado entre N, S y O; R4 y R5 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo sustituido con flúor de 1 a 10 carbonos, fenilalquilo, naftilalquilo y heteroarilalquilo, teniendo el alquilo en dichos grupos fenilalquilo, naftilalquilo y heteroarilalquilo 1 a 10 carbonos; R6, es hidrógeno, halógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con flúor, alcoxi que tiene 1 a 10 carbonos o alcoxi sustituido con flúor que tiene 1 a 10 carbonos; R6 a R9 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con halógeno, alcoxi de 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con halógeno, alquil carbonilo, alcoxicarbonilo teniendo el grupo alquilo en dicho alquil carbonilo y alcoxicarbonilo 1 a 10 carbonos, oxazolilo, imidazolilo, tiazolilo, pirazolilo o cualquiera de los dos adyacentes a los grupos R6 a R9 puede formar un anillo que puede incluir opcionalmente un heteroátomo seleccionado entre N, O y S; R10 es hidrógeno, alquilo de 1 a 10 carbonos; R11 y R12 se seleccionan independientemente entre hidrógeno, halógeno, alquilo de 1 a 10 carbonos y alquilo de 1 a 10 carbonos sustituido con halógeno; R15 tiene la fórmula siguiente **(Fórmula)** en donde R17 es alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con halógeno, alcoxi que tiene 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con halógeno, alquiltio que tiene 1 a 10 carbonos, alquiltio de 1 a 10 carbonos sustituido con halógeno, alcoxi carbonilo que tiene 1 a 10 carbonos, alcoxi carbonilo que tiene 1 a 10 carbonos sustituido con halógeno, F, Cl, Br, I, NO2, CN, OCOalquilo, NH2, alquilamino y dialquilamino, en donde en dichos grupos OCOalquilo, alquilamino y dialquilamino cada uno de dichos grupos alquilo tiene 1 a 10 carbonos, carbamoílo, carbamoílo sustituido en N, alquilcarbonilo que tiene 1 a 10 carbonos, grupos (alcoxicarbonil)alcoxi en donde cada uno de dichos grupos alcoxi tiene 1 a 10 carbonos, grupos (alcoxicarbonil)alquilo en donde cada uno de dichos grupos alcoxi o alquilo tiene 1 a 10 carbonos, (carbamoil)alcoxi que tiene 1 a 10 carbonos, (N-alquilcarbamoil)alcoxi que tiene 1 a 10 carbonos, (N, N-dialquilcarbamoil)alcoxi que tiene 1 a 10 carbonos, poli((carbamoil sustituido en N o no sustituido)alcoxi) que tiene 1 a 10 carbonos, (carbamoil sustituido en N o no sustituido)alquilo que tiene 1 a 10 carbonos, [N-(heteroaril)carbamoil]alquilo que tiene 1 a 10 carbonos, [N-(heteroaril)carbamoil]alcoxi que tiene 1 a 10 carbonos, [N-(heteroaril sustituido)carbamoil]alcoxi que tiene 1 a 10 carbonos, [N-(aril sustituido)carbamoil]alcoxi que tiene 1 a 10 carbonos, grupo poli(alcoxi) en donde cada uno de dichos grupos alcoxi tiene 1 a 10 carbonos, polialcoxi cíclico, grupo guanidinilo, grupo ureido, grupo poli(dialquilamino - alcoxi), [N - (carbamoilalquil)carbamoil]alcoxi, [N - (carbamoilalquil)carbamoil]alquilo, [N - [[N - (heteroaril)carbamoil]alquil]carbamoil]alcoxi, [N - [[N - (heteroaril sustituido)carbamoil]alquil]carbamoil]alcoxi, [(tri - alquil)amonio]alcoxi, (sulfonato)alquilo, (sulfonato)alcoxi, N - [sulfonato)alquil]amido, maleimido (sustituido), succinimido (sustituido); y R21 es (aril)alquilo, (heteroaril)alquilo, fenilo, naftilo o heteroarilo que tiene 1 a 3 heteroátomos seleccionados independientemente entre N, O y S, estando dichos grupos fenilo, naftilo o heteroarilo, sustituidos o no sustituidos con 1 a 5 grupos R17, o a una sal farmacéuticamente aceptable de dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/131,481 US6093734A (en) | 1998-08-10 | 1998-08-10 | Prodrugs of proton pump inhibitors |
| US36438199A | 1999-07-29 | 1999-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2192394T3 true ES2192394T3 (es) | 2003-10-01 |
Family
ID=26829517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99942057T Expired - Lifetime ES2192394T3 (es) | 1998-08-10 | 1999-08-09 | Profarmacos de inhibidores de la bomba de protones. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6559167B1 (es) |
| EP (1) | EP1105387B1 (es) |
| JP (1) | JP4346243B2 (es) |
| KR (1) | KR100472126B1 (es) |
| CN (1) | CN100396675C (es) |
| AT (1) | ATE231857T1 (es) |
| AU (1) | AU752292B2 (es) |
| BG (1) | BG64870B1 (es) |
| BR (1) | BR9912937A (es) |
| CA (1) | CA2338311C (es) |
| DE (1) | DE69905171T2 (es) |
| DK (1) | DK1105387T3 (es) |
| ES (1) | ES2192394T3 (es) |
| FI (1) | FI20010248A (es) |
| HK (1) | HK1035368A1 (es) |
| HR (1) | HRP20010106A2 (es) |
| HU (1) | HUP0103464A3 (es) |
| ID (1) | ID28273A (es) |
| IL (2) | IL141083A0 (es) |
| IS (1) | IS5826A (es) |
| MX (1) | MXPA01001464A (es) |
| NO (1) | NO322490B1 (es) |
| NZ (1) | NZ510180A (es) |
| PL (1) | PL346000A1 (es) |
| TR (1) | TR200100431T2 (es) |
| UA (1) | UA67788C2 (es) |
| WO (1) | WO2000009498A1 (es) |
| YU (1) | YU10101A (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050020637A1 (en) * | 2001-11-19 | 2005-01-27 | Wolfgang-Alexander Simon | Agents for the treatment of airway disorders |
| US6897227B2 (en) | 2002-07-19 | 2005-05-24 | Winston Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors |
| JP2006188432A (ja) * | 2003-02-25 | 2006-07-20 | Zeria Pharmaceut Co Ltd | 四環系スルフェンアミド化合物 |
| NZ544173A (en) * | 2003-07-15 | 2009-04-30 | Alevium Pharmaceuticals Inc | Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors |
| AU2004268641A1 (en) * | 2003-08-29 | 2005-03-10 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastrointestinal motility disorders |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| WO2005039640A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
| US20070161679A1 (en) * | 2004-02-18 | 2007-07-12 | Allergan, Inc. | Method and compositions for the intravenous administration of compounds related to proton pump inhibitors |
| JP2007523163A (ja) * | 2004-02-18 | 2007-08-16 | アラーガン、インコーポレイテッド | プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物 |
| CA2561700A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| WO2005105786A1 (en) * | 2004-04-28 | 2005-11-10 | Hetero Drugs Limited | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
| DE602004025386D1 (de) * | 2004-05-28 | 2010-03-18 | Hetero Drugs Ltd | Neue stereoselektive synthese von benzimidazolsulfoxiden |
| NZ552093A (en) * | 2004-06-17 | 2009-06-26 | Wyeth Corp | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| WO2006009734A1 (en) * | 2004-06-17 | 2006-01-26 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| RU2007110731A (ru) * | 2004-09-23 | 2008-10-27 | Редди Юс Терапевтикс | Новые соединения пиримидина, способ их получения и содержащие их композиции |
| WO2006058012A2 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US7582634B2 (en) * | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
| US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| CA2611917A1 (en) * | 2005-06-13 | 2006-12-21 | Takeda Pharmaceutical Company Limited | Injection |
| WO2007073301A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Benzoimidazole derivatives as prodrugs of proton pump inhibitors |
| US20100317689A1 (en) * | 2006-09-19 | 2010-12-16 | Garst Michael E | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
| WO2008036211A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| EP2486910A3 (en) | 2006-10-27 | 2012-08-22 | The Curators Of The University Of Missouri | Multi-chambered apparatus comprising a dispenser head |
| CN101497622B (zh) * | 2008-01-30 | 2011-04-27 | 山东轩竹医药科技有限公司 | 吡啶甲基亚磺酰基咪唑并吡啶衍生物 |
| EP2252274A4 (en) | 2008-02-20 | 2011-05-11 | Univ Missouri | COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME |
| UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| BR112015010908A2 (pt) * | 2012-11-19 | 2017-07-11 | Jiangsu Hansoh Pharmaceutical Co Ltd | derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo |
| MY176887A (en) | 2013-02-28 | 2020-08-25 | Takeda Pharmaceuticals Co | Method for producing sulfonyl chloride compound |
| SI3762368T1 (sl) | 2018-03-08 | 2022-06-30 | Incyte Corporation | Aminopirazin diolne spojine kot zaviralci PI3K-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| JP2023527155A (ja) | 2020-05-20 | 2023-06-27 | エフ． ホフマン－ラ ロシュ アーゲー | 質量分析のための試薬 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| SE8505112D0 (sv) * | 1985-10-29 | 1985-10-29 | Haessle Ab | Novel pharmacological compounds |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| PL166209B1 (pl) * | 1990-06-20 | 1995-04-28 | Astra Ab | Sposób wytwarzania nowych pochodnych benzimidazolu PL |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| SE9602442D0 (sv) | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
-
1999
- 1999-08-09 CN CNB998095125A patent/CN100396675C/zh not_active Expired - Fee Related
- 1999-08-09 TR TR2001/00431T patent/TR200100431T2/xx unknown
- 1999-08-09 JP JP2000564950A patent/JP4346243B2/ja not_active Expired - Fee Related
- 1999-08-09 DK DK99942057T patent/DK1105387T3/da active
- 1999-08-09 MX MXPA01001464A patent/MXPA01001464A/es not_active IP Right Cessation
- 1999-08-09 BR BR9912937-0A patent/BR9912937A/pt not_active Application Discontinuation
- 1999-08-09 KR KR10-2001-7001705A patent/KR100472126B1/ko not_active IP Right Cessation
- 1999-08-09 PL PL99346000A patent/PL346000A1/xx not_active IP Right Cessation
- 1999-08-09 EP EP99942057A patent/EP1105387B1/en not_active Expired - Lifetime
- 1999-08-09 ES ES99942057T patent/ES2192394T3/es not_active Expired - Lifetime
- 1999-08-09 ID IDW20010545A patent/ID28273A/id unknown
- 1999-08-09 IL IL14108399A patent/IL141083A0/xx active IP Right Grant
- 1999-08-09 AU AU55518/99A patent/AU752292B2/en not_active Expired
- 1999-08-09 AT AT99942057T patent/ATE231857T1/de not_active IP Right Cessation
- 1999-08-09 HU HU0103464A patent/HUP0103464A3/hu unknown
- 1999-08-09 WO PCT/US1999/018048 patent/WO2000009498A1/en active IP Right Grant
- 1999-08-09 DE DE69905171T patent/DE69905171T2/de not_active Expired - Lifetime
- 1999-08-09 NZ NZ510180A patent/NZ510180A/xx not_active IP Right Cessation
- 1999-08-09 YU YU10101A patent/YU10101A/sh unknown
- 1999-08-09 CA CA002338311A patent/CA2338311C/en not_active Expired - Lifetime
- 1999-09-08 UA UA2001020908A patent/UA67788C2/uk unknown
-
2001
- 2001-01-24 IL IL141083A patent/IL141083A/en not_active IP Right Cessation
- 2001-01-26 BG BG105191A patent/BG64870B1/bg unknown
- 2001-01-26 IS IS5826A patent/IS5826A/is unknown
- 2001-02-09 NO NO20010693A patent/NO322490B1/no not_active IP Right Cessation
- 2001-02-09 HR HR20010106A patent/HRP20010106A2/hr not_active Application Discontinuation
- 2001-02-09 FI FI20010248A patent/FI20010248A/fi unknown
- 2001-02-14 US US09/783,807 patent/US6559167B1/en not_active Expired - Lifetime
- 2001-08-24 HK HK01105985A patent/HK1035368A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2192394T3 (es) | Profarmacos de inhibidores de la bomba de protones. | |
| FI831604L (fi) | Pyridinderivat, deras framstaellning och anvaendning | |
| AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
| ES2190264T3 (es) | N-(2-aril-propionil)sulfonamidas y preparaciones farmaceuticas que las contienen. | |
| DE69929689D1 (de) | Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen | |
| PT93111A (pt) | Processo para a preparacao de compostos heterociclicos contendo pelo menos dois atomos de azoto no anel | |
| HUP0301555A2 (hu) | Szubsztituált szulfonilaminometilbenzoesav-származékok és eljárás előállításukra | |
| RU2004119406A (ru) | 5-сульфанил-4н-1,2,4-триазольные производные и их применение в качестве лекарственного препарата | |
| AR057244A1 (es) | Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes. | |
| EA200001172A1 (ru) | Терапевтические диарильные производные | |
| DE69412534D1 (de) | Piperazin-Derivate und ihre Verwendung als Calmodulin-Inhibitoren | |
| HUP0402026A2 (hu) | 5,6-Diaril-pirazin-2-amid-származékok mint CB1 antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| RU2001111023A (ru) | Новые производные n-(иминометил)аминов, их получение, их использование в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| ES2075849T3 (es) | Derivados heterociclicos. | |
| BG100511A (en) | Indole derivatives as nmda antagoniosts | |
| RU2004119963A (ru) | Ингибиторы вич интегразы | |
| RU2003132582A (ru) | Лекарственное средство для хронического суставного ревматизма | |
| RU97103983A (ru) | Лекарственные композиции и производные триазина | |
| RU2002129100A (ru) | Гетероциклические производные и лекарственные средства | |
| CO4810374A1 (es) | Nueva utilizacion de compuestos para actividad anti- pruritica | |
| DK270289A (da) | Oligopeptider med cycliske, prolin-analoge aminosyrer og farmaceutisk acceptable salte deraf samt deres anvendelse | |
| DE3785803D1 (de) | 4-cyano(nitro)-5-oxy(thio)-pyrazol-derivate. | |
| GB1369401A (en) | Process for the manufacture of 2-amino-1,4-dihydropyridines and their use as coronary agents | |
| RU2003130752A (ru) | Противозудные средства | |
| DE68925933D1 (de) | Arylalkylamine und -amide mit krampflösender und nervenschützender Wirkung |